Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
mirdametinib + carbamazepine
- Development stage
- Unknown
- Lead developer
- SpringWorks Therapeutics
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
mirdametinib + carbamazepine is a drug combination used in a Phase 1 clinical pharmacology study to evaluate the pharmacokinetic drug-drug interaction between mirdametinib, a MEK1/2 inhibitor, and carbamazepine, a strong CYP3A4 inducer. Mirdametinib (brand name Gomekli) is developed by SpringWorks Therapeutics for the treatment of neurofibromatosis type 1 (NF1) associated plexiform neurofibromas. Carbamazepine is an anticonvulsant that induces various cytochrome P450 enzymes. The study aims to determine how the induction of CYP3A4 by carbamazepine affects the systemic exposure and elimination of mirdametinib in healthy volunteers.
- Other names
- mirdametinib and carbamazepine
02
Targets
CYP3A4 (Cytochrome P450 3A4)MEK1 (Dual specificity mitogen-activated protein kinase kinase 1)NaV (Voltage-gated sodium channels)MEK2 (Dual specificity mitogen-activated protein kinase kinase 2)
Beyond the preview
Go deeper on mirdametinib + carbamazepine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on mirdametinib + carbamazepine.